Handling worker and third-party exposures to nanotherapeutics during clinical trials
about
Risks to health care workers from nano-enabled medical productsPotential applications and human biosafety of nanomaterials used in nanomedicineDefining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?Rethinking risk assessment for emerging technology first-in-human trials.Naming it 'nano': Expert views on 'nano' terminology in informed consent forms of first-in-human nanomedicine trials.Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.
P2860
Handling worker and third-party exposures to nanotherapeutics during clinical trials
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials
@nl
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@ast
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en-gb
type
label
Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials
@nl
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@ast
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en-gb
prefLabel
Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials
@nl
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@ast
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en-gb
P2860
P921
P1476
Handling worker and third-party exposures to nanotherapeutics during clinical trials
@en
P2093
Andrew Maynard
Martin Philbert
P2860
P2880
P304
P356
10.1111/J.1748-720X.2012.00714.X
P577
2012-12-01T00:00:00Z